2 November 2017 - The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis.

The guidelines green light funding for routine use of the drug on the National Health Service in England in combination with methotrexate as a treatment option for adults whose disease has responded inadequately to intensive therapy with conventional or other disease modifying anti-rheumatic drugs (DMARDs).

The guidance also recommends for monotherapy in adults with severe, active rheumatoid arthritis who are intolerant to MTX and cannot have rituximab.

Read Pharma Times article